These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 32484365)

  • 1. Cost of fremanezumab, erenumab, galcanezumab and onabotulinumtoxinA associated adverse events, for migraine prophylaxis in Spain.
    Irimia P; Santos-Lasaosa S; García Bujalance L; Ramos Pinazo L; Rubio-Rodríguez D; Rubio-Terrés C
    Expert Rev Pharmacoecon Outcomes Res; 2021 Apr; 21(2):285-297. PubMed ID: 32484365
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece.
    Giannouchos TV; Mitsikostas DD; Ohsfeldt RL; Vozikis A; Koufopoulou P
    Clin Drug Investig; 2019 Oct; 39(10):979-990. PubMed ID: 31302899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States.
    Tepper SJ; Fang J; Zhou L; Shen Y; Vo P; Abdrabboh A; Glassberg MB; Ferraris M
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1157-1170. PubMed ID: 33998825
    [No Abstract]   [Full Text] [Related]  

  • 4. Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective.
    Lipton RB; Brennan A; Palmer S; Hatswell AJ; Porter JK; Sapra S; Villa G; Shah N; Tepper S; Dodick D
    J Med Econ; 2018 Jul; 21(7):666-675. PubMed ID: 29571276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study.
    Alex A; Vaughn C; Rayhill M
    Headache; 2020 Nov; 60(10):2454-2462. PubMed ID: 32969035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: Results from the US societal and payer perspectives.
    Sussman M; Benner J; Neumann P; Menzin J
    Cephalalgia; 2018 Sep; 38(10):1644-1657. PubMed ID: 30142988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials.
    Xu D; Chen D; Zhu LN; Tan G; Wang HJ; Zhang Y; Liu L
    Cephalalgia; 2019 Aug; 39(9):1164-1179. PubMed ID: 30789292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Network meta-analysis on efficacy and safety of different anti-CGRP monoclonal antibody regimens for prophylaxis and treatment of episodic migraine.
    Shi M; Guo J; Li Z; Sun H; Yang X; Yang D; Zhao H
    Neurol Res; 2021 Nov; 43(11):932-949. PubMed ID: 34281473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fremanezumab (Ajovy) and galcanezumab (Emgality) for migraine prevention.
    Med Lett Drugs Ther; 2018 Nov; 60(1559):177-180. PubMed ID: 30681655
    [No Abstract]   [Full Text] [Related]  

  • 10. Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting System.
    Silberstein SD; Reshef S; Cohen JM; Gandhi S; Seminerio M; Ramirez Campos V; Kessler Y; Thompson SF; Blumenfeld A
    Adv Ther; 2023 Feb; 40(2):445-459. PubMed ID: 36350532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double-blind studies.
    Ailani J; Pearlman E; Zhang Q; Nagy AJ; Schuh K; Aurora SK
    Eur J Neurol; 2020 Mar; 27(3):542-549. PubMed ID: 31595600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Erenumab, Galcanezumab, and Fremanezumab in the Treatment of Drug-Resistant Chronic Migraine: Experience in Real Clinical Practice.
    Cantarelli L; Pestana Grafiña D; Gonzalez Perez A; García Gil S; Gutiérrez Nicolás F; Ramos Santana E; Navarro Dávila MA; Otazo Pérez SM; Calzado Gómez G; Perez Reyes S; Nazco Casariego GJ
    Ann Pharmacother; 2023 Apr; 57(4):416-424. PubMed ID: 35979920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine.
    Khanal S; Underwood M; Naghdi S; Brown A; Duncan C; Matharu M; Mistry H
    J Headache Pain; 2022 Sep; 23(1):122. PubMed ID: 36114468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison study between erenumab, fremanezumab, and galcanezumab in the preventive treatment of high frequency episodic migraine and chronic migraine.
    Quintana S; Russo M; Manzoni GC; Torelli P
    Neurol Sci; 2022 Sep; 43(9):5757-5758. PubMed ID: 35802220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK.
    Batty AJ; Hansen RN; Bloudek LM; Varon SF; Hayward EJ; Pennington BW; Lipton RB; Sullivan SD
    J Med Econ; 2013 Jul; 16(7):877-87. PubMed ID: 23647483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: Analysis of the WHO pharmacovigilance database.
    Noseda R; Bedussi F; Gobbi C; Zecca C; Ceschi A
    Cephalalgia; 2021 Jun; 41(7):789-798. PubMed ID: 33435709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eptinezumab (Vyepti) for migraine prevention.
    Med Lett Drugs Ther; 2020 Jun; 62(1599):85-87. PubMed ID: 32555116
    [No Abstract]   [Full Text] [Related]  

  • 18. Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine.
    Mechtler L; Saikali N; McVige J; Hughes O; Traut A; Adams AM
    Front Neurol; 2021; 12():788159. PubMed ID: 35069416
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis.
    Deng H; Li GG; Nie H; Feng YY; Guo GY; Guo WL; Tang ZP
    BMC Neurol; 2020 Feb; 20(1):57. PubMed ID: 32061264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
    Tepper S; Ashina M; Reuter U; Brandes JL; Doležil D; Silberstein S; Winner P; Leonardi D; Mikol D; Lenz R
    Lancet Neurol; 2017 Jun; 16(6):425-434. PubMed ID: 28460892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.